Adam R. Craig - 12 Aug 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Executive Chairman, Director
Signature
/s/ David Kirske, Attorney-In-Fact
Issuer symbol
XFOR
Transactions as of
12 Aug 2025
Transactions value $
$0
Form type
4
Filing time
14 Aug 2025, 20:31:21 UTC
Previous filing
26 Jun 2023
Next filing
27 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Craig Adam R Executive Chairman, Director C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON /s/ David Kirske, Attorney-In-Fact 14 Aug 2025 0001339498

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $0 +290K $0.00 290K 14 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XFOR Stock Option (right to buy) Award $0 +1.61M $0.00 1.61M 12 Aug 2025 Common Stock 1.61M $1.42 Direct F2
transaction XFOR Stock Option (right to buy) Award $0 +529K $0.00 529K 14 Aug 2025 Common Stock 529K $3.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.
F2 One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.